Important information about coverage for Digital Breast Tomosynthesis (DBT) or 3-D mammography

In 2015, the USPSTF reviewed screening recommendations for breast cancer and concluded in a draft recommendation statement that Digital Breast Tomosynthesis (DBT) or 3-D mammography does not meet evidence level A or B and should not be recommended in place of digital mammography for routine breast cancer screening. The draft statement also notes that DBT may expose women to approximately twice the radiation of 2-D digital mammography. Based on the USPSTF conclusion and Anthem Blue Cross’ independent review of the available evidence, Anthem Blue Cross considers Digital Breast Tomosynthesis investigational and not medically necessary for all indications.